Learn how the 12-year biologic exclusivity rule under the BPCIA delays biosimilar entry, impacting drug prices and patient access in the US compared to global markets.
Mar, 30 2026
Aug, 22 2025
Aug, 26 2025
Oct, 31 2025
Jun, 22 2026